Related Experiment Video
Updated: Mar 14, 2026
06:10
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
3.7K
Ivabradine: Do the Benefits Outweigh the Risks?
11 Department of Clinical Pharmacy, College of Pharmacy, University of Hail, Hail, Saudi Arabia.
Journal of Cardiovascular Pharmacology and Therapeutics
|October 5, 2016
Summary
Ivabradine effectively lowers heart rate for angina and heart failure patients. Its benefit-risk profile is favorable, especially for those with heart rates ≥70 bpm, despite expected bradycardia side effects.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Ivabradine selectively inhibits the If current to reduce heart rate (HR).
- It is approved for angina and heart failure in multiple countries.
- Concerns exist regarding its HR-lowering effects and potential for bradycardia.
Purpose of the Study:
- To assess the benefit-risk balance of ivabradine.
- To analyze efficacy and safety data from clinical trials and ADR reports.
Main Methods:
- Literature review of major published studies on ivabradine's efficacy and safety.
- Analysis of adverse drug reaction (ADR) reports from the VigiBase system.
Main Results:
- Most studies indicate beneficial effects and a tolerable safety profile for ivabradine.
- A favorable benefit-risk profile was observed in patients with HR ≥70 bpm.
- Bradycardia was the most common ADR, as expected; other risks were comparable to other drugs.
Conclusions:
- Ivabradine demonstrates an acceptable and favorable benefit-risk profile.
- It is a viable treatment option for patients with angina pectoris and chronic heart failure.
Related Concept Videos
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
2.5K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.5K
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
2.2K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.2K
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
3.9K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
3.9K
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
2.8K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.8K
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.4K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
1.7K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.7K